Epcoritamab for older or frailer adults with large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of large B-cell lymphoma, like DLBCL or transformed lymphoma.
- You must not have had any prior lymphoma treatment (for the first-line group) or have had only one prior treatment that included specific chemotherapy and antibody drugs (for the second-line group).
- Your cancer must be measurable on a PET scan.
- You must be considered 'frail' or 'unfit' (for first-line) or not be a candidate for a stem cell transplant (for second-line).
- You must have adequate liver, kidney, and blood counts, and be able to stay within 60 minutes of the clinic for 24 hours after a certain dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.